Loading
A phase 2 trial of HS-20093, Rezvilutamide, Abiraterone acetate in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer is a phase 2 interventional study registered as NCT07230106 by Jiangsu HengRui Medicine Co., Ltd., with 218 participants planned, started 2025-12-08 and due to reach its primary completion in 2028-12. Interventions recorded: HS-20093 for Injection, SHR3680 Tablet, Abiraterone Tablet, SHR2554 Tablet, Enzalutamide Tablet. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs), Prostate cancer.
Shares Rezvilutamide, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Jiangsu Hengrui Pharmaceuticals, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/